Research
What a drug company and the regulator say to each other
Most of the relationship between a sponsor and the agency is conversation, not decisions. Two sentences in the rules govern what that conversation is worth: one says advice binds nobody, the other says a written agreement does.
A long conversation with two hard edges
A drug program is often described as a series of verdicts. In the rules it looks more like a correspondence that occasionally produces one.
Four short sections set out how a sponsor and the agency talk: comment and advice, meetings, waivers, and what happens when they disagree.
Two sentences inside them decide what any of that talk is worth. One makes ordinary advice non-binding on everybody. The other gives a recorded agreement real force.
The distinction is useful outside a trial too, because company claims about agency contact are common and rarely say which kind of contact they mean.
Advice, offered and requested
The agency may communicate with a sponsor at any time during an investigation, orally or in writing, about deficiencies in the application or about its need for more data.
The sponsor can also ask. On request, the agency will provide advice on specific matters relating to the application.
The rule gives examples of what those matters look like. The adequacy of technical data to support an investigational plan. The design of a clinical trial.
And a third that is more forward-looking: whether proposed investigations are likely to produce the data and information needed to meet the requirements for a marketing application.
That is a company asking, in advance, whether the studies it has planned would be enough. It is one of the more valuable things the arrangement offers.
The sentence that limits all of it
Immediately after describing that advice, the rule states what it is not.
Unless a communication is accompanied by a clinical hold order, agency communications with a sponsor under this section are solely advisory.
They do not require any modification in the planned or ongoing clinical investigations, and they do not require a response to the agency.
So the ordinary channel produces guidance that binds nobody, in either direction. The company need not act on it, and the agency has not committed to anything by giving it.
That is the correct lens for any claim that a company has spoken to the regulator, or that the regulator has expressed a view. Unless a hold is attached, a conversation is a conversation.
Meetings, and the principle written into the rule
Meetings get their own section, and it opens with an unusually direct statement of purpose.
The agency encourages such meetings to the extent that they aid in evaluating the drug and in solving scientific problems, and to the extent its resources permit.
The general principle underlying the conduct of such meetings is that there should be free, full and open communication about any scientific or medical question that may arise during the investigation.
Those meetings are conducted and documented under the agency's general administrative practices, which is the part that turns a conversation into a record.
The meeting that produces a presumption
Two moments are singled out as especially useful, and the first sits between the second and third phases of study.
Its purpose is to determine the safety of proceeding to the third phase, and to evaluate the plan and protocols for it. It also assesses the adequacy of pediatric plans and identifies additional information needed to support a marketing application.
Eligibility is broad. While the meeting is designed primarily for applications involving new molecular entities or major new uses, a sponsor of any application may request and obtain one.
The preparation is specified. At least one month in advance the sponsor submits background information. That includes summaries of the earlier phases, the specific protocols for the next one, plans for further nonclinical and pediatric studies, and tentative labeling if available.
And then the sentence that makes the meeting matter. Agreements reached are recorded in minutes taken by the agency and provided to the sponsor, and those minutes serve as a permanent record.
Barring a significant scientific development that requires otherwise, studies conducted in accordance with the agreement are presumed to be sufficient in objective and design for the purpose of obtaining marketing approval.
Why that presumption is the interesting part
Read the two sentences together and the structure is clear. Casual advice binds nobody; a documented agreement about study design creates a presumption in the company's favor.
The presumption is about objective and design, not about results. It does not promise approval, and it does not say the drug works.
It says that if the company runs the studies both sides agreed to, nobody will later argue those studies were the wrong shape.
That is the mechanism by which an expensive program becomes plannable. It is also why the minutes exist, and why the rule bothers to say who takes them.
The meeting before the application
The second named meeting happens near the end of the third phase, before a marketing application is filed.
Its primary purpose is to uncover any major unresolved problems, and to identify which studies the sponsor is relying on as adequate and well-controlled to establish effectiveness.
It also covers the status of pediatric studies, acquaints reviewers with what is coming, and settles how the data will be analyzed statistically and presented.
The sponsor supplies material a month ahead: a brief summary of the clinical studies to be submitted, a proposed format for organizing the submission, and the status of pediatric work.
Identifying which studies carry the effectiveness claim, in advance, is the same discipline as agreeing a design in advance. It removes the option of deciding afterward which evidence to lean on.
Asking to be excused from a rule
Requirements in the part can be waived, and the process for it is short and conditional.
A sponsor may request a waiver, either in the application itself or in an information amendment. In an emergency the request may be made by telephone or other rapid communication.
The request must contain at least one of three things. An explanation why compliance is unnecessary or cannot be achieved. A description of an alternative that satisfies the purpose of the requirement. Or other information justifying a waiver.
Granting one has a gate in front of it. The agency may grant a waiver only if it finds that the noncompliance would not pose a significant and unreasonable risk to human subjects.
Beyond that gate, one of three findings is needed. That compliance is unnecessary for the agency to evaluate the application, or cannot be achieved. That the proposed alternative satisfies the requirement. Or that the submission otherwise justifies it.
The order matters. Risk to participants is checked first, and no amount of justification reaches the second test if the first one fails.
When they disagree
The last of the four sections handles disagreement, and it splits it in two.
Administrative and procedural disputes start with the reviewing division, beginning with the consumer safety officer assigned to the application. If that does not resolve it, the sponsor may raise the matter with a person designated as ombudsman.
That role is described functionally: to investigate what has happened and to facilitate a timely and equitable resolution. The examples given are scheduling difficulties and slow replies.
Scientific and medical disputes go a different way. The sponsor discusses the matter with the responsible reviewing officials, and may request a meeting with them and with management representatives.
Outside opinion can be brought in from either side. The sponsor may suggest that the agency seek advice from outside experts, and may rely on and bring its own consultants to any meeting.
For major unresolved scientific or policy questions, the agency may refer the matter to one of its standing advisory committees.
What a reader can do with all of this
None of this correspondence is public while it happens, so the value here is in knowing what the categories are.
When a company says it has been in contact with the regulator, the question is which channel. Ordinary advice is solely advisory unless a hold came with it.
When a company describes an agreement, the question is whether it was reached at a documented meeting and recorded in minutes, because that is the kind that carries a presumption.
When a company says a requirement does not apply to it, the waiver test is the shape to check. Was the request made, and would the noncompliance pose a significant and unreasonable risk to people.
And when a company describes a disagreement with the agency, notice which half it fell in. A scheduling complaint and a dispute about whether the evidence is adequate travel different routes for a reason.
Key takeaways
- Ordinary communications between the agency and a sponsor are solely advisory unless accompanied by a clinical hold order.
- A sponsor may ask whether its planned investigations are likely to produce the data a marketing application would need.
- The stated principle for meetings is free, full and open communication about any scientific or medical question arising during an investigation.
- Agreements reached at the meeting between the second and third phases are recorded in agency minutes that serve as a permanent record.
- Studies run in accordance with such an agreement are presumed sufficient in objective and design for the purpose of seeking approval, barring a significant scientific development.
- A waiver of a requirement may be granted only where the noncompliance would not pose a significant and unreasonable risk to human subjects.
- Disputes split into administrative ones, which reach an ombudsman, and scientific ones, which reach reviewing officials and possibly an advisory committee.
Frequently asked questions
Is advice from the agency binding on a company?
No, and the rule says so directly. Unless a communication is accompanied by a clinical hold order, agency communications with a sponsor under that section are solely advisory. They do not require any modification in the planned or ongoing clinical investigations, and they do not require a response to the agency.
What can a sponsor ask the agency about?
Specific matters relating to its application. The rule gives examples. The adequacy of technical data to support an investigational plan. The design of a clinical trial. And whether proposed investigations are likely to produce the data needed to meet the requirements for a marketing application. The agency may also raise deficiencies or ask for more data at any time.
What makes a meeting different from ordinary advice?
The record and the consequence. Agreements reached at the meeting between the second and third phases are recorded in minutes taken by the agency and provided to the sponsor, and those minutes are a permanent record. Barring a significant scientific development requiring otherwise, studies conducted in accordance with the agreement are presumed sufficient in objective and design for the purpose of obtaining marketing approval.
Does that presumption mean the drug will be approved?
No. It attaches to objective and design, not to results. It means the shape of the studies is settled, so a program that follows the agreement will not later be told it ran the wrong studies. Whether the data show what the company hoped is a separate question the presumption does not touch.
Can a company be excused from a requirement?
It can request a waiver, in the application or in an information amendment, and in an emergency by telephone or other rapid communication. The request must explain why compliance is unnecessary or unachievable, describe an alternative that satisfies the purpose, or otherwise justify it. The agency may grant one only if it finds the noncompliance would not pose a significant and unreasonable risk to human subjects.
What happens when a sponsor and the agency disagree?
Administrative and procedural disputes go to the reviewing division first, beginning with the assigned consumer safety officer, and then to a designated ombudsman whose role is to investigate and facilitate resolution. Scientific and medical disputes go to the responsible reviewing officials, with meetings available, outside consultants on either side, and referral to a standing advisory committee for major unresolved questions.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 312.10 — Waivers — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.41 — Comment and advice on an IND — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.47 — Meetings — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.48 — Dispute resolution — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026